Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rEV131
- Development stage
- Phase 2
- Lead developer
- Nanoco
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical, Ophthalmic, Intranasal, Inhalation
01
Overview
rEV131 is a topically delivered small protein investigational anti-inflammatory agent developed for the treatment of allergic rhinitis, asthma, and several inflammatory eye diseases. It has been studied in clinical trials for conditions such as ocular inflammation after cataract surgery and seasonal allergic rhinitis. The drug was developed by Evolutec Group. Its mechanism of action is not fully characterized or publicly disclosed, but it is described as having anti-inflammatory properties. Clinical trials have reached up to Phase 2; however, at least one Phase IIb trial in allergic rhinitis did not meet its primary endpoint[1][4][5][7].
Beyond the preview
Go deeper on rEV131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rEV131.